Dr Reddys Open To Making Pfizer Covid Pill Post Deal With Merck

Dr Reddys Open To Making Pfizer Covid Pill Post Deal With Merck

By, Admin 12 September 2021

The New Drugs, Which Unlike Vaccines Can Be Used To Treat Patients Once They Contract Coronavirus Infection, Are Expected To Be A Huge Market.The New Drugs, Which Unlike Vaccines Can Be Used To Treat Patients Once They Contract Coronavirus Infection, Are Expected To Be A Huge Market.Yeah, Yeah, Absolutely," Dr. Reddy'S Co-Chairman And Managing Director, G.V. Prasad, Told Reuters In An Interview, When Asked About Making Rival Products From The U.S. Companies."Dr. Reddy'S Remains Open To All Opportunities," A Company Spokesperson Said Separately.Prasad Said Dr Reddy'S, One Of India'S Biggest Drugmakers, Had Not Yet Initiated Any Talks With Pfizer (Pfe.N) Before The U.S. Company Sought Regulatory Permissions.Dr. Reddy'S Expects India'S Drug Regulator To Approve Merck'S Molnupiravir As Soon As The United States Does. Britain And Bangladesh Have Already Authorised The Drug, And India With Its 1.35 Billion People Could Be A Big Market.India Is Also Processing The Application. Merck Is Also Submitting The Data Here," Prasad Said. "Approval Is Expected As Soon As Merck Gets Approval In The U.S."Molnupiravir, Which Merck Will Itself Market As Lagevrio, Was Shown Last Month To Halve The Chance Of High-Risk Covid-19 Patients Dying Or Being Hospitalised. The Chance Is Cut By 89% For Adults At Risk Of Severe Disease In The Case Of Pfizer'S Drug, Paxlovid.Other Licensed Indian Molnupiravir Producers Include Aurobindo Pharma, Cipla, Emcure Pharmaceuticals, Sun Pharmaceuticals, Torrent Pharmaceuticals And Hetero Labs. Their Deal With Merck Allows Them To Sell The Product In India And Some Other Developing Countries.Merck Has Signed Deals To Sell More Than 6 Million Courses Of Molnupiravir Around The World. Bangladesh'S Beximco Pharmaceuticals Said Last Week It Would Sell A Version Of The Drug For 70 Taka (82 Cents) Per Capsule, Or 2,800 Taka ($33) For A Full Course.Prasad Said Demand Would Dictate Its Production Of The Merck Drug, Foreseeing A Tough Fight Between The Indian Companies."In The End, It Will Be A Race To The Bottom, It Will Be Very Competitive," He Said. "There'S Not A Lot Of Money To Be Made With These Products."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!